By Marie Ng - Affiliate Associate Professor of Global Health, University of Washington In the United States, the overweight ...

Despite the rising competition in the obesity space, we believe that there is room for smaller biotechs like Viking Therapeutics to grab a share of this booming market.

Adult obesity rates in the United States dropped from 46% in 2022 to 45.6% in 2023, according to the new study published in ...

(HealthDay News) — The mean body mass index (BMI) and prevalence of obesity declined in the United States in 2023, according to research published in JAMA Health Forum.

Novo Nordisk NVO shares have plunged 17.9% in a week due to poorer-than-expected efficacy data from a late-stage study of its ...

but not for long Eli Lilly is still slightly behind Novo Nordisk in terms of market share of the incretin class in obesity in the United States, but this is more a reflection of the inability of ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

That’s a positive indicator, one doctor says, but developing healthier eating habits ‘would be much better than people just losing weight.’ ...

Lilly's own obesity injection - sold as Zepbound in the United States - led to an average weight loss of nearly 23% in clinical trials. The data from Novo's CagriSema Phase III trial was based on ...

A self-confessed "morbidly obese British man" has taken to TikTok to reveal what he eats in a day whilst holidaying in the United States. Cory, who has travelled to New York City with his wife ...

According to 2017 to 2018 National Health and Nutrition Examination Survey results, 42.5% of U.S. adults 20 years old and over have obesity. Older data from the same survey states that adults with ...